Betrixaban

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Betrixaban
Betrixaban structure.png
Systematic (IUPAC) name
N-(5-chloropyridin-2-yl)-2-([4-(N,N-dimethylcarbamimidoyl)benzoyl]amino)-5-methoxybenzamide
Clinical data
Legal status ?
Identifiers
CAS number 330942-05-7 N
ATC code None
PubChem CID 10275777
ChemSpider 18981107 YesY
UNII 74RWP7W0J9 YesY
ChEMBL CHEMBL512351 YesY
Chemical data
Formula C23H22ClN5O3 
Mol. mass 451.905 g/mol
 N (what is this?)  (verify)

Betrixaban (INN, codenamed PRT-054,021) is an anticoagulant drug which acts as a direct factor Xa inhibitor.[1] It is potent, orally active and highly selective for factor Xa, being selected from a group of similar compounds for its low hERG affinity.[2] Betrixaban has undergone human clinical trials for prevention of embolism after knee surgery,[3] and prevention of stroke following atrial fibrillation,[4] with promising results.[5]Joint development with Portola was discontinued in 2011 by Merck.[6]

See also[edit]

References[edit]

  1. ^ Eriksson BI, Quinlan DJ, Weitz JI (2009). "Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development". Clinical Pharmacokinetics 48 (1): 1–22. doi:10.2165/0003088-200948010-00001. PMID 19071881. 
  2. ^ Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA, Probst GD, Song Y, Su T, Fan J, Wu Y, Li W, Woolfrey J, Sinha U, Wong PW, Edwards ST, Arfsten AE, Clizbe LA, Kanter J, Pandey A, Park G, Hutchaleelaha A, Lambing JL, Hollenbach SJ, Scarborough RM, Zhu BY (April 2009). "Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor". Bioorganic & Medicinal Chemistry Letters 19 (8): 2179–85. doi:10.1016/j.bmcl.2009.02.111. PMID 19297154. 
  3. ^ Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, Sinha U, Gretler DD (January 2009). "A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)". Thrombosis and Haemostasis 101 (1): 68–76. doi:10.1160/th08-07-0460. PMID 19132191. 
  4. ^ Piccini, J. P.; Lopes, R. D.; Mahaffey, K. W. (2010). "Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation". Current Opinion in Cardiology 25 (4): 312. doi:10.1097/HCO.0b013e32833a524f. PMID 20520539.  edit
  5. ^ Sobieraj-Teague, M.; O’donnell, M.; Eikelboom, J. (2009). "New Anticoagulants for Atrial Fibrillation". Seminars in Thrombosis and Hemostasis 35 (5): 515–24. doi:10.1055/s-0029-1234147. PMID 19739042.  edit
  6. ^ Husten, Harry. "Merck Abandons Development of Factor Xa Inhibitor Betrixaban". CardioBrief. Retrieved 11 April 2014.